CA-BATTERY-SHOW/EV-TECH
27.4.2021 12:04:13 CEST | Business Wire | Press release
The Battery Show & EV Tech Europe Digital Days , a three-day digital event, strategically scheduled for 18-20 May to connect and educate industry professionals during a time of immense disruption via technical sessions, panels, networking opportunities, and digital sourcing, today announced the second raft of speakers confirmed to address the advanced battery and hybrid & electric vehicle (H/EV) tech community. Executives and senior-level experts from 3M, EnBW, McLaren Applied, Punch Powertrain, Renault, among many others, will present novel solutions and lead technical demonstrations that address the industry's leading challenges. The online conference will run adjacent to the digital exhibition floor that features hundreds of leading companies including Parker/LORD, Siemens, and TE Connectivity.
Registration for the digital conference and exhibition is open to attendees and press:
As the effects of the ongoing COVID-19 pandemic continue to impact grid storage, battery materials, battery-powered electric vehicles, and manufacturer supply chains, the European region is presented with unprecedented stressors amid exceptional market acceleration. Speaking to the importance and timeliness of the event, James Frith, Head of Energy Storage at Bloomberg New Energy Finance and chair of the keynote panel “Meeting Demand for EV Battery Production in Europe; The Rise of the Giga Factory,” said: "The European battery manufacturing industry has been turned on its head over the last three years, going from almost non-existent to the second largest market globally. The Digital Days event will be the perfect opportunity to find out how the companies at the heart of this change envisage the next decade."
"At the rate the advanced battery and H/EV tech sectors are progressing in the European region and the number of obstacles that require an immediate solution, we felt it was critical to orchestrate industry connection before our next in-person event in November," said Rob Shelton, group event director, The Battery Show & EV Tech Europe Digital Days, Informa Markets. "The level of support for the upcoming digital event permeates all corners of the industry and is a clear indicator of the battery and H/EV tech market's fortitude and future advancement."
Featured conference content includes:
Tuesday 18 May
EV Forecasts: 2020 Summary of European EV Market Expansion and its Implications on Battery Demand
Speaker: Viktor Irle, Co-Founder & Market Analyst, EV Volumes
Latest Developments in EV Architectures: Determining the Optimum Level of Hybridization versus Societal, Environmental, and Economic Benefits
Speaker: Marcin Seredynski, Head of Innovation and Research, E-Bus Competence Centre
Race to Road Debate: Examining Formula E & Hyper Car Architectures and How they Can be Adapted for the Mass Market EV
Moderator: Luke Gear, Technology Analyst, IDTechEx
- Angus Lyon, Director, Rockfort Engineering
- Yu Merla, Principal Engineer - Advanced Battery Projects, Williams Advanced Engineering
- Wasim Sarwar, Head of Research and Advanced Engineering, Rimac Automobil
Wednesday 19 May
EV Technical Session: The Role of Electric Vehicles in the Energy Transition
Speaker: Jeremy Parkes, Global Business Lead - Electric Vehicles, DNV
Keynote (Open to All) – Leaders Panel: Meeting Demand for EV Battery Production in Europe; the Rise of the Giga Factory
Moderator: James Frith, Senior Energy Storage Analyst, Bloomberg New Energy Finance
- Benoit Lemaignan, CEO, Verkor
- Kai-Uwe Wollenhaupt, President Europe & Vice President, SVOLT Energy Technology Company Ltd
- Sebastian Wolf, Sr Director EU Operations and Managing Director, Farasis Energy Europe
- Gery Bonduelle, SVP Sales, Freyr
- Allan Paterson, CTO, Britishvolt
Electric Motor Development: Faster Charging, Higher Efficiency, Longer Range: The next Step in Electrification
Steve Lambert, Head of Electrification, McLaren Applied
Electric Powertrain: Developing High-Speed Electric Drive Unit for the Next Generation
Speaker: Henrik Dhejne, Product Line Manager - Passenger Car Transmissions, electrified Transmission & e-Axle, AVL
Thursday 20 May
EV Technical Session: State of the art Electric Track Drive for Medium & Heavy-Duty Machines
Speaker: Massimo Palomba, Global Sales Manager E-Mobility, Bonfiglioli Mobility & Wind Industries, Bonfiglioli Spa
EV Technical Session: HEV Battery Design; Should it be for Second Life or Easy to Recycle?
Speaker: Paweł Swoboda, Business Development Manager, BMZ Poland
Electric Buses: If 70% Of EV Cost is in The Battery… How Can You Reduce the Cost of Electrification?
Speaker: Manos Polioudis, Head of Powertrain Engineering, Arrival
For the full The Battery Show & EV Tech Europe Digital Days conference agenda, please visit here .
Follow The Battery Show & EV Tech Europe Digital Days on social media: #TheBatteryShow
About Informa Markets – Engineering:
Informa Markets' Engineering portfolio is the leading B2B event producer, publisher, and digital media business for the world's $3-trillion advanced, technology-based manufacturing industry. Our print and electronic products deliver trusted information to the engineering market and leverage our proprietary 1.3-million-name database to connect suppliers with buyers and purchase influencers. We produce more than 50 events and conferences in a dozen countries, connecting manufacturing professionals from around the globe. The Engineering portfolio is organized by Informa, the world's leading exhibitions organizer that brings a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com .
About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Engineering, Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and, do business through face-to-face exhibitions, specialist digital content and, actionable data solutions. As the world's leading exhibitions organizer, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005048/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom